- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 25/00 - Drugs for disorders of the nervous system
Patent holdings for IPC class A61P 25/00
Total number of patents in this class: 18252
10-year publication summary
|
655
|
706
|
1008
|
1193
|
1281
|
1350
|
1424
|
1428
|
1257
|
520
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| F. Hoffmann-La Roche AG | 7926 |
282 |
| The Regents of the University of California | 19812 |
186 |
| Janssen Pharmaceutica N.V. | 3423 |
185 |
| Takeda Pharmaceutical Company Limited | 2704 |
172 |
| Hoffmann-La Roche Inc. | 3379 |
138 |
| Glaxo Group Limited | 4132 |
105 |
| AstraZeneca AB | 2928 |
99 |
| Novartis AG | 10904 |
96 |
| H. Lundbeck A/S | 1229 |
91 |
| Centre National de La Recherche Scientifique | 10321 |
87 |
| Neurosearch A/S | 189 |
85 |
| Daiichi Sankyo Company, Limited | 1852 |
84 |
| The Johns Hopkins University | 5642 |
83 |
| sanofi-aventis | 374 |
83 |
| Sage Therapeutics, Inc. | 362 |
81 |
| Pfizer Inc. | 3367 |
78 |
| Boehringer Ingelheim International GmbH | 4704 |
71 |
| Bristol-myers Squibb Company | 4892 |
69 |
| Osaka University | 3362 |
69 |
| Allergan, Inc. | 2362 |
59 |
| Other owners | 16049 |